

AD \_\_\_\_\_

GRANT NUMBER: DAMD17-94-J-4221

TITLE: Breast Cancer: Involvement of Epidermal Growth Factor  
Receptor, MDM2, and p53 Mutations

PRINCIPAL INVESTIGATOR: Dr. John Meyers

CONTRACTING ORGANIZATION: University of Texas  
Health Science Center  
San Antonio, TX 78284-7758

REPORT DATE: October 1996

TYPE OF REPORT: Annual

PREPARED FOR: Commander  
U.S. Army Medical Research and Materiel Command  
Fort Detrick, Frederick, MD 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19970220 075

# REPORT DOCUMENTATION PAGE

Form Approved

OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

<b>1. AGENCY USE ONLY (Leave blank)</b>		<b>2. REPORT DATE</b> October 1996	<b>3. REPORT TYPE AND DATES COVERED</b> Annual (15 Sep 95 - 14 Sep 96)	
<b>4. TITLE AND SUBTITLE</b> Breast Cancer: Involvement of Epidermal Growth Factor Receptor, MDM2, and p53 Mutations			<b>5. FUNDING NUMBERS</b> DAMD17-94-J-4221	
<b>6. AUTHOR(S)</b>  Dr. John Meyers				
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b>  University of Texas Health Science Center San Antonio, TX 78284-7758			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> Commander U.S. Army Medical Research and Materiel Command Fort Detrick, MD 21702-5012			<b>10. SPONSORING/MONITORING AGENCY REPORT NUMBER</b>	
<b>11. SUPPLEMENTARY NOTES</b>				
<b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b>  Approved for public release; distribution unlimited			<b>12b. DISTRIBUTION CODE</b>	
<b>13. ABSTRACT (Maximum 200)</b>  The human epidermal growth factor receptor (EGFR) promoter is activated by both wild-type and tumor-derived mutant p53. In this report we demonstrate that the EGFR promoter is activated by tumor-derived p53 mutants p53-143A, p53-175H, p53-248W, p53-275H and p53-281G. Using p53-281G as a model we show that the transactivation by mutant p53 requires different protein domains than wild-type p53 and does not require the wild-type p53-binding site. The minimal EGFR promoter from positions -104 to -20 which does not contain the wild-type p53-binding site is transactivated by the p53 mutants but not wild-type protein. Together the domain requirements and promoter sequence requirements indicate a difference in the mechanism of transactivation by wild-type and mutant p53. Transactivation of the EGFR promoter by mutant p53s may represent a mechanism by which tumor cells lose cell growth control.				
<b>14. SUBJECT TERMS</b>  Breast Cancer			<b>15. NUMBER OF PAGES</b> 19	
			<b>16. PRICE CODE</b>	
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited	

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

       Where copyrighted material is quoted, permission has been obtained to use such material.

       Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

  X   Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

       In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

  X   For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

  X   In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

  X   In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

       In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

*John H. Under Meyer*  
PI - Signature

10/12/96  
Date

## TABLE OF CONTENTS

	page
Front Cover.....	1
SF 298 report Documentation.....	2
Foreword.....	3
Table of Contents.....	4
Introduction.....	5
Materials and Methods.....	7
Results.....	8
Discussion.....	10
References.....	12

## LIST OF FIGURES

Figure 1.....	15
Figure 2.....	16
Figure 3.....	17
Bibliography.....	18

## INTRODUCTION

p53 is a tumor suppressor that negatively regulates the cell cycle(11, 27, 28, 32, 34). Mutation in the p53 gene is a very common somatic genetic change found in human cancer(11, 17, 23, 27, 28, 32, 34,). Although the p53 gene is not required for normal development in mice, lack of p53 function confers an enormously elevated risk of developing cancer. p53 seems to regulate cell growth, at least in part, by transcriptional control. The level of wild-type p53 in normal cells is very low, but when cells are exposed to genotoxic stimuli, p53 levels rise rapidly and initiate a program of cell death or stop the cell cycle at the G<sub>1</sub>/S boundary, presumably for DNA repair. This "guardian-of-genome" (27)response of wild-type p53 is lost in many tumor cells because they have either inactivated their p53 genes by mutation or blocked the activity of p53 through the production of proteins that bind to it and neutralize it.

Wild-type p53 is a sequence-specific DNA-binding protein(11, 27, 28, 34). The DNA binding domain of wild-type p53 has been identified to be the central region of the protein covering conserved domains II to V(2, 7, 21, ). Wild-type p53 also has a strong transcriptional activation domain (amino acids 1 to 42) (14, 35, ). As expected, wild-type p53 is a sequence-specific transactivator for promoters with p53-binding sites(11, 27, 28, 34). Tumor-derived p53 mutants are in general defective in this sequence-specific transactivation. Several prospective target genes whose expression may be positively influenced by wild-type p53 have been identified. These include murine muscle creatine kinase, MDM2 (1,33), CIP1/WAF1/p21 (12), epidermal growth factor receptor (EGFR) (10), thrombospondin-1 (16), GADD45, Bax, human transforming growth factor alpha (36), insulinlike growth factor-binding protein 3 (3), human proliferating-cell nuclear antigen (PCNA) (2, 30, 37) and cyclin G (31).

Several groups have also demonstrated that overexpression of wild-type (but not mutant) human p53 inhibits the *in vivo* transcription of many cellular and viral promoters which lack p53-binding sites (9, 15, 39-41). p53-mediated transcriptional repression is released by adenovirus E1B p19 or cellular Bcl-2 proteins, suggesting that repression may be a part of the sequence of events in apoptosis (35). We and others have also reported that some cancer-derived p53 mutants activate the promoters of genes expressing PCNA, EGFR, multiple drug resistance MDR1, vascular endothelial growth factor, human interleukin-6, basic fibroblast growth factor and human heat shock protein 70 (HSP70) (6, 9, 42). This transactivation represents the only known biochemical "gain of function" for tumor-derived p53 mutants. Two critical hydrophobic amino acids (positions 22 and 23) in the N-terminal transactivation domain of mutant p53 are required for gain of function as judged by tumorigenesis assays and by transactivation of the MDR1 promoter suggesting that the transactivation ability of mutant p53 is required for gain of function.

Growth factors modulate cell growth and differentiation via interaction with their receptors. Epidermal growth factor (EGF) stimulates cell growth by directly activating its receptor (EGFR), leading to signal transduction through an intracellular cascade of second messengers (5, 13). EGFR is a transmembrane glycoprotein of 170 kDa with an extracellular EGF-binding domain (4, 5, 13). EGFR acquires oncogenic properties when its structure or regulation becomes disrupted, as was found in transformed cells, tumors, and established cell lines (13, 36, 38,). Thus, regulation of EGFR transcription should be

critical for normal cell growth and proliferation. Earlier, we demonstrated that human p53 activates the EGFR promoter in a dose-dependent manner in vivo (10). This suggests that the p53 growth regulatory pathway may intersect the pathway used by growth factors to regulate cell proliferation. We have now shown that transforming mutants of p53 also activate the EGFR promoter. This observation may signify a pathway by which mutant p53 may induce cell proliferation.

Three promoters, EGFR (10), MDR1 (6, 16), and PCNA (9, 16,) are transactivated by both wild-type and mutant p53. In last year's annual report we described the identification and characterization of a wild-type p53 DNA binding sequence in the EGFR promoter. This DNA sequence was shown to be required for wild-type mediated transactivation of the EGFR promoter. That data will be published in the November 1996 issue of Molecular and Cellular Biology. In the present study we have examined EGFR promoter transactivation by tumor-derived p53 mutants. We show that activation of the EGFR promoter by mutant p53 requires promoter sequences previously identified as the basal promoter (26). This promoter element does not contain the wild-type p53 response element indicating different mechanisms of transactivation between wild-type and mutant p53. Analysis of the p53 protein domains required for activation of the EGFR revealed that domain requirements also differ between wild-type and mutant p53.

## MATERIALS AND METHODS

**DNA plasmids.** The p53 expression plasmids contain a wild-type or mutant p53 cDNA under the regulation of the human cytomegalovirus immediate-early promoter in the pCMV-Bam expression vector (22, 39). The series of N- and C-terminal deletion derivatives were generated as described previously (41).

The chloramphenicol acetyl transferase (CAT) plasmids utilized the *Escherichia coli* CAT gene under the transcriptional control of human EGFR promoter sequences. The 3' end of each of the following EGFR-CAT constructs (26, a gift from Glenn T. Merlino) is at -20 relative to the EGFR translation start site, while the 5' ends map to the following restriction sites and positions: pERCAT-1 (Hind III, -1109); pERCAT-9 (Ava II, -389) and pERCAT-15 (Ava I, -104). pER-1.CAT is a plasmid with the EGFR upstream sequences from -1109 to -20 cloned upstream of the CAT gene in the pCATbasic vector (Promega) (10).

**Cell culture and transfection.** Human osteosarcoma (Saos-2) cells were cultured and transfected by the calcium phosphate-DNA coprecipitation method, as described previously (39). In a typical experiment,  $1-2 \times 10^6$  cells were cotransfected with 2.5 ug of a CAT construct and 5 ug of a p53 expression plasmid (or 5 ug of the expression vector without p53 sequences as a negative control). All transfection experiments were repeated multiple times (three times or more).

**CAT assay.** Cells were harvested 36 to 40 h posttransfection and lysed by three successive cycles of freezing and thawing. Extracts were normalized for protein concentration and assayed for CAT activity (39). Because mutant p53s activate different promoters to different extents (9, 10, 15, 39), it was not possible for us to use an internal control such as pSV $\beta$ Gal or RSV $\beta$ Gal. A similar situation has been recognized for simian virus 40 T antigen-mediated regulation of promoters(18). Therefore, we have done multiple independent experiments with different DNA preparations and calculated the standard deviations. CAT activity was detected by thin-layer chromatographic separation of [ $^{14}$ C]chloramphenicol from its acetylated derivatives followed by autoradiography. Quantitation was done with a Phosphorimager (Molecular Dynamics).



## RESULTS

**Wild-type human p53 and its tumor-derived mutants transactivate the human EGFR promoter.** To compare the transactivation efficiencies of wild-type and tumor-derived p53, we performed transient-transfection assays with a promoter-CAT construct containing the entire EGFR promoter (pER-1.CAT) (10). We transfected Saos-2 cells with pER-1.CAT and wild-type p53 or mutant p53 expression plasmids (or expression vector alone). Figure 1 shows a representative CAT assay result. p53 levels were analyzed by Western blot (immunoblot) analysis of the protein extracts used for the CAT assays. Even taking into account the variation of the level of p53 expressed, wild-type p53 remains the weakest and p53-281G is the strongest transactivator (data not shown). Thus, p53 mutants differ in their transactivation efficiency from each other and from the wild-type protein.

**Protein domains required for mutant p53-mediated transcriptional activation of the human EGFR promoter.** In the previous annual report the amino terminus of wild-type p53 was shown to be required for activation of the EGFR promoter while the carboxy terminal 66 amino acids are dispensable. Further deletion of the C-terminus eliminated wild-type transactivation. To determine the domain requirements of mutant p53 for transactivation of the EGFR promoter a similar set of amino- and carboxy-terminal deletions were made in the mutant p53 protein. Saos-2 cells were cotransfected with pER-1.CAT (containing the EGFR promoter from -1109 to -20) (10) and with a plasmid expressing either the mutant p53-281G protein or one of its N- or C-terminal deletion derivatives (or with the pCMV-Bam expression vector). The results in Fig. 2B indicate requirements for the N-terminal transactivation domain and the C-terminal region involved in oligomerization and non-sequence-specific DNA binding. In Fig. 2A the domain requirements for wild-type p53 transactivation of the EGFR promoter are given (previously presented in the October 1995 annual report) to allow comparison. The C-terminal domain requirements differ for transactivation of the EGFR promoter by wild-type and mutant p53 (compare del 393-327). This indicates a possible difference in mechanism of transactivation used by wild-type and mutant p53.

**Activation of the minimal EGFR promoter by p53-281G.** To determine the sequence requirements for transactivation by p53-281G, we used a set of EGFR promoter deletion mutants (Fig 3A) (kind gifts from G. Merlino). We performed cotransfection experiments in Saos-2 cells with different promoter deletion mutant-CAT constructs and the p53-281G expression plasmid (or expression vector alone). Figure 3B depicts a representative CAT assay result. All the deletion mutants, including the one with a deletion up to -104 (ER-1  $\Delta$ AvaI) were activated significantly by p53-281G (Fig. 3B, compare lanes 1 and 2, lanes 3 and 4, and lanes 5 and 6). The EGFR upstream sequences up to -104 define the minimal promoter of EGFR (26). These results suggest that p53-281G activates the minimal EGFR promoter possibly by interacting with the machinery required for basal transcription. This observation is similar to that observed for the PCNA, human immunodeficiency virus long terminal repeat, and human HSP70 promoters (9, 10, 40, 42.). It is significant that wild-type p53 does not transactivate the minimal EGFR promoter without the p53-binding site (October 1995 annual report,) showing that



the mechanisms of transactivation of the EGFR promoter by wild-type and mutant p53 are different.

## DISCUSSION

In this report we present evidence that tumor-derived mutants of p53 transactivate the EGFR promoter, a promoter we previously observed to contain a wild-type p53 transcriptional response element (October 1995 annual report,). We show that the p53-binding site is not required for transactivation by the mutant proteins (Fig. 3) consistent with the previous demonstration that baculovirus purified p53-281G does not bind to the this site (October 1995 annual report,). The minimal promoter defined by the *Ava*I deletion mutant of the EGFR promoter is activated efficiently by tumor-derived p53 mutants. Mutant p53-mediated transactivation of the EGFR promoter requires the oligomerization domain, whereas wild-type p53-mediated transactivation does not (Fig. 2). These results suggest that mutant proteins use a different mechanism to transactivate the EGFR promoter. Since many tumor-derived p53 mutants are defective in sequence-specific DNA binding (11, 27, 28, 34), it is possible that mutant p53 activates the EGFR promoter after being recruited on the DNA by some other transcription factor. Since the EGFR minimal promoter is activated by mutant p53, it could serve as a simple model to understand mutant p53-mediated transactivation.

The minimal EGFR promoter has one Sp1-binding site, and transcription from the minimal promoter is dependent on Sp1 (43). Since Sp1-mediated transcriptional activation may involve TAF<sub>II</sub>110 and TAF<sub>II</sub>250 (24), involvement of the Sp1/TAF<sub>II</sub>110/TAF<sub>II</sub>250 system in mutant p53-mediated transactivation may be speculated. Involvement of Sp1 in p53-mediated transactivation has been noted previously for transactivation of HIV LTR (19, 20). The EGFR minimal promoter also contains a thyroid hormone receptor binding site which overlaps the Sp1 binding site. This element has been shown to inhibit Sp1 dependent transcription in the presence of ligand activated thyroid hormone receptor and retinoic acid receptors(43). Interestingly, it has been observed that p53 binds to thyroid hormone receptors in vitro and some tumor-derived mutant p53s increase human thyroid receptor  $\beta$ 1 dependent transcription (44). The *Ava*I deletion mutant of the EGFR promoter also contains element(s) that confer responsiveness to phorbol 12-myristate 13-acetate (PMA). This responsiveness was due, in part, to a functional activator protein 2 (AP-2) DNA binding site. A consensus binding site for activator protein 1 (AP-1) was identified, by DNA sequence comparison, within this same EGFR promoter fragment and may contribute to the PMA responsiveness (25). Thus, the EGFR promoter *Ava*I deletion is an important regulatory element that contains multiple transcription factor binding sites and is also the minimal sequence required for tumor-derived mutant p53-mediated transcriptional activation.

Our lab has previously shown that mutant p53 activates transcription from synthetic Sp1, NF- $\kappa$ B and ATF binding sites (40). This has lead to the hypothesis that tumor-derived mutant p53 may act as a co-activator of transcription. This function would "bridge" transcription factors to the basal transcription machinery necessitating transcription factor binding sites for mutant p53 transcriptional activation. Deletion and point mutations of the EGFR *Ava*I deletion fragment are being made to identify transcription factor binding sites, and thus the transcription factor(s) required for mutant p53-mediated transcriptional activation. The identified transcription factor(s) will be analyzed for the ability to interact with mutant and wild-type p53 proteins. Also, studies

are under way to determine if mutant p53 interacts with proteins associated with the basal transcription apparatus (such as the TATA-binding protein, TF<sub>II</sub>B and TAF<sub>II</sub>250). Both activities are consistent with the function of a transcriptional co-activator.

## REFERENCES


1. **Barak, Y., T. Juven, R. Haffner, and M. Oren.** 1993. MDM2 expression is induced by wild-type p53 activity. *EMBO J.* 12:461-468.
2. **Bargonetti, J., J. J. Manfredi, X. Chen, D. R. Marshak, and C. Prives.** 1993. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. *Genes Dev.* 7:2565-2574.
3. **Buckbinder, L., R. Talbott, S. Velasco-Miguel, I. Takenaka, B. Faha, B. R. Selzinger, and N. Kley.** 1995. Induction of the growth inhibitor IGF-binding protein 3 by p53. *Nature (London)* 377:646-649.
4. **Carpenter, G.** 1987. Receptors for epidermal growth factor and other polypeptide mitogens. *Annu. Rev. Biochem.* 56:881-914.
5. **Carpenter, G., and S. Cohen.** 1990. Epidermal growth factor. *J. Biol. Chem.* 265:7709-7712.
6. **Chin, K.-V., K. Ueda, Il Pastan, and M. M. Gottesman.** 1992. Modulation of activity of the promoter of the human MDR1 gene by ras and p53. *Science* 255:459-462.
7. **Cho, Y., S. Gorina, P. D. Jeffrey, and N. P. Pavletich.** 1994. Crystal structure of a tumor suppressor-DNA complex: understanding tumorigenic mutations. *Science* 265:346-355.
8. **Dameron, K. M., O. V. Volpert, M. A. Tainsky, and N. Bouck.** 1994. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. *Science* 265:1582-1584.
9. **Deb, S., C. T. Jackson, M. A. Subler, and D. W. Martin.** 1992. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. *J. Virol.* 66:6164-6170.
10. **Deb, S. P., R. M. Munoz, D. R. Brown, M. A. Subler, and S. Deb.** 1994. Wild-type human p53 activates the human epidermal growth factor receptor promoter. *Oncogene* 9:1341-1350.
12. **Donehower, L. A., and A. Bradley.** 1993. The tumor suppressor p53. *Biochim. Biophys. Acta* 1155:185-205.
13. **El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, D. W. Kluzler, and B. Vogelstein.** 1993. WAF1, a potential mediator of p53 tumor suppression. *Cell* 75:817-825.
14. **Fantl, S. J., D. E. Johnson, and L. T. Williams.** 1993. Signalling by receptor tyrosine kinases. *Annu. Rev. Biochem.* 62:453-481.
15. **Glusberg, D., F. Mechta, M. Yaniv, and M. Oren.** 1991. Wild-type p53 can down-modulate the activity of various promoters. *Proc. Natl. Acad. Sci. USA* 88:9979-9983.
16. **Goldsmith, M. E., J. M. Gudas, E. Schneider, and K. H. Cowan.** 1995. Wild-type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line. *J. Biol. Chem.* 270:1894-1898.

17. **Greenblatt, M. S., W. P. Bennet, M. Hollstein, and C. C. Harris.** 1994. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. *Cancer Res.* 54:4855-4878.
18. **Gruda, M. C., J. M. Zabolotny, J. H. Xiao, I. Davidson, and J. C. Alwine.** 1993. Transcriptional activation by simian virus 40 large T antigen: interaction with multiple components of the transcription complex. *Mol. Cell. Biol.* 13:961-969.
19. **Gualberto, A., and A. S. Baldwin.** 1995. p53 and Sp1 interact and cooperate in the tumor necrosis factor-induced transcriptional activation of the HIV-1 long terminal repeat. *J. Biol. Chem.* 270:19680-19683.
20. **Gualberto, A., M. L. Hixon, T. S. Ginco, N. D. Perkins, G. J. Nabel, and A. S. Baldwin.** 1995. A proliferative p53-responsive element mediates tumor necrosis factor alpha induction of the human immunodeficiency virus type 1 long terminal repeat. *Mol. Cell. Biol.* 15:3450-3459.
21. **Halazonetis, T. D., and A. N. Kandil.** 1993. Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. *EMBO J.* 12:5057-5064.
22. **Hinds, P. W., C. A. Finlay, R. S. Quartin, S. J. Baker, E. R. Fearon, B. Vogelstein and A. J. Levine.** 1990. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. *Cell Growth Differ.* 1:571-580.
23. **Hollstein, M., K. Rice, M. S. Greenblatt, T. Soussi, R. Fuchs, T. Sorlle, E. Hovig, B. Smith-Sorensen, R. Montesano, and C. C. Harris.** 1994 Database of p53 gene somatic mutations in human tumors and cell lines. *Nucleic Acids Res.* 22:3551-3555.
24. **Hoye, T., R. O. J. Weinzierl, G. Gill, J.-L. Chen, B. D. Dynlacht, and R. Tijan.** 1993 Molecular cloning and functional analysis of drosophila TAF110 reveals properties expected of coactivators. *Cell* 72:247-260.
25. **Johnson, A. C.** 1996. Activation of Epidermal Growth Factor Receptor Gene Transcription by Phorbol 12-Myristate 13-Acetate Is Mediated by Activator Protein 2. *Proc. Natl. Acad. Sci. USA* 271:3033-3038.
26. **Johnson, A. C., S. Ishi, Y. Jinno, I. Pastan, and G. T. Merlino.** 1988. Epidermal growth factor receptor gene promoter. deletion analysis and identification of nuclear protein binding sites. *J. Biol. Chem.* 263:5693-5699.
27. **Lane, D. P.** 1994. p53 and human cancers. *Br. Med. Bull.* 50:582-599.
28. **Levine, A. J.** 1993. The tumor suppressor genes. *Annu. Rev. Biochem.* 62:623-651.
29. **Levine, A. J., J. Momand, and C. A. Finlay.** 1991. The p53 tumor suppressor gene. *Nature (London)* 351:453-456.
30. **Morris, G. F., J. R. Bischoff, and M. B. Mathews.** 1996. Transcriptional activation of the human proliferating cell nuclear antigen promoter by p53. *Proc. Natl. Acad. Sci. USA* 93:895-899.
31. **Okamoto, K., and D. Beach.** 1994. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. *EMBO J.* 13:4816-4822.

32. **Ozbun, M. A., and J. S. Butel.** 1995. Tumor suppressor p53 mutations and breast cancer: a critical analysis. *Ann. Cancer Res.* 66:71-141.
33. **Perry, M. E., J. Piette, J. A. Zawadzki, D. Harvey, and A. J. Levine.** 1993. The mdm-2 gene is induced in response to UV light in a p53-dependent manner. *Proc. Natl. Acad. Sci. USA* 90:11623-11627.
34. **Prives, C.** 1994. How loops, beta sheets, and alpha helices help us to understand p53. *Cell* 78:543-548.
35. **Raycroft, L., H. Wu, and G. Lozano.** 1990. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. *Science* 249:1049-1051.
36. **Shin, T. H., A. J. Paterson, and J. E. Kudlow.** 1995. p53 stimulates transcription from the human transforming growth factor alpha promoter: a potential growth stimulatory role for p53. *Mol. Cell. Biol.* 15:4694-4701.
37. **Shivakumar, C., D. R. Brown, S. Deb, and S. P. Deb.** 1995. Wild-type p53 activates the human proliferating cell nuclear antigen promoter. *Mol. Cell. Biol.* 15:6785-6793.
38. **Stoscheck, C. M., and L. E. King.** 1985. Role of epidermal growth factor in carcinogenesis. *Cancer Res.* 46:1030-1037.
39. **Subler, M. A., D. W. Martin, and S. Deb.** 1992 Inhibition of viral and cellular promoters by human wild-type p53. *J. Virol.* 66:4757-4762.
40. **Subler, M. A., D. W. Martin, and S. Deb.** 1994. Activation of the HIV-1 LTR by transforming mutants of human p53. *J. Virol.* 68:103-110.
41. **Subler, M. A., D. W. Martin, and S. Deb.** 1994 Overlapping domains on the p53 protein regulate its transcriptional activation and repression functions. *Oncogene* 9:1351-1359.
42. **Tsutsumi-Ishi, Y., K. Tadokoro, F. Hanaoka, and N. Tsuchida.** 1995. Response of heat shock element within the human HSP70 promoter to mutated p53 genes. *Cell Growth Differ.* 6:1-8.
43. **Xu, J., K. L. Thompson, L. B. Shephard, L. G. Hudson, and G. N. Gill.** 1993. T3 receptor suppression of Sp1-dependent transcription from the epidermal growth factor receptor promoter via overlapping DNA-binding sites. *J. Biol. Chem.* 268:16065-160773.
44. **Yap, N., C.-L. Yu, and S.-Y. Cheng.** 1996. Modulation of the transcriptional activity of thyroid hormone receptors by the tumor suppressor p53. *Proc. Natl. Acad. Sci.* 93:4273-4277.

## FIGURES

**A.**



**B.**




FIG. 1. Effect of expression of wild-type p53 and its tumor-derived mutants on EGFR promoter function in Saos-2 cells. Saos-2 cells were transfected with 2.5 ug of EGFR.CAT (pER-1.CAT) containing EGFR promoter sequences from -1109 to -20 upstream of the bacterial CAT gene and 5 ug of vector alone or 5 ug of an expression plasmid for wild-type (WT) p53 or one of its mutants (p53-143A, p53-175H, p53-248W, p53-273H or p53-281G). After transfection, cells were treated as described in Material and Methods. (A) Representative CAT assay result. The average fold transactivations by wild-type and mutant p53 are as follows: wild-type p53,  $3.03 \pm 0.55$ ; p53-143A,  $4.15 \pm 2.15$ ; p53-175H,  $4.62 \pm 1.01$ ; p53-248W,  $5.12 \pm 0.75$ ; p53-273H,  $12.4 \pm 5.05$ ; p53-281G,  $15.2 \pm 3.36$ . (B) Western blot analysis carried out with equal amounts of protein from each CAT assay extract, using a monoclonal antibody (Pab1801 [Ab2]; Oncogene Science). The position of the p53 band is shown by an arrow






FIG. 2. Protein domain requirements for transcriptional activation of the human EGFR promoter by wild-type (WT) p53 (A) and its mutant derivative p53-281G (B). To determine the domains on the wild-type and mutant protein required for p53-mediated transactivation of the human EGFR promoter, a series of N- and C-terminal deletion derivatives was used. Saos-2 cells were cotransfected with 2.5 ug of pER-1.CAT (containing the EGFR promoter from -1109 to -20) along with 5 ug of a plasmid expressing either the intact p53 protein or one of its N- or C-terminal deletion derivatives (or with 5 ug of the pCMV-Bam expression vector).




FIG. 3. Activation of the minimal EGFR promoter by p53-281G. Saos-2 cells were transfected with 5 ug of pCMV p53-281G (or expression vector alone without insert) and 2.5 ug of pER-1.CAT or one of the promoter deletion mutants shown at the top. (A) EGFR promoter deletion mutants used in the assays. The p53-binding site is indicated. (B) CAT assays were performed as described in Materials and Methods. The average fold transactivations of different promoter deletion mutants by wild-type human p53 are as follows: pER-1.CAT (promoter extending up to HindIII at -1109),  $26 \pm 18$ ; pER-1.CAT del AvaII,  $33.6 \pm 26$ ; pER-1.CAT del AvaI,  $16.5 \pm 5.9$ . (C) Western blot analysis carried out with equal amounts of protein from each CAT assay extract, using a monoclonal anti-p53 antibody (Pab1801 [Ab2]; Oncogene Science).

## BIBLIOGRAPHY

John H. Ludes-Meyers Ph. D. is the sole personnel receiving pay from the negotiated effort.

Below are abstracts from one publication and one scientific meeting resulting from the funds provided by this grant:

### **Transcriptional Activation of the Human Epidermal Growth Factor Receptor Promoter by Human p53**

JOHN H. LUDES-MEYERS, MARK A. SUBLER, CHITTARI V. SHIVAKUMAR, RUBEN M. MUNOZ, PENG JIANG, JOHN E. BIGGER, DORIS R BROWN, SWATI PALIT DEB, AND SUMITRA DEB

The human epidermal growth factor receptor (EGFR) promoter is activated by both wild-type and tumor-derived mutant p53. In this communication, we demonstrate that EGFR promoter sequence requirements for transactivation by wild-type and mutant p53 are different. Transient-expression assays with EGFR promoter deletions identified a wild-type human p53 response element, 5'-AGCTAGACGTCCGGGCAGCCCCGGCG-3', from positions -265 to -239. Electrophoretic mobility shift analysis and DNase I footprinting assays indicated that wild-type p53 binds sequence specifically to the response element. Using circularly permuted DNA fragments containing the p53-binding site, we show that wild-type p53 binding induces DNA bending at this site. We further show that the EGFR promoter is also activated by tumor-derived mutants p53-143A, p53-175H, p53-248W, p53-273H, p53-281G. However, the transactivation by mutant p53 does not require the wild-type p53-binding site. The minimal EGFR promoter from positions -104 to -20 which does not contain the wild-type p53-binding site is transactivated by the p53 mutants but not the wild-type protein, showing a difference in the mechanism of transactivation by wild-type and mutant p53. Transactivation of the EGFR promoter by p53 may represent a novel mechanism of cell growth regulation.

**DIFFERENTIAL INVOLVEMENT OF TAF<sub>II</sub>250 IN p53-MEDIATED REGULATION OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR PROMOTER.** John H. Ludes-Meyers, Mark A. Subler, Chittari V. Shivakumar, Doris R. Brown, Swati Palit Deb, and Sumitra Deb, Department of Microbiology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78284

While p53 is an intracellular regulator of cell proliferation, epidermal growth factor modulates cell growth by binding to the extracellular domain of its receptor (EGFR). We demonstrate that the human EGFR gene promoter is transcriptionally activated by both wild-type p53 and tumor derived mutants. We performed a structure-function analysis of wild-type p53 and p53-281G. *In vivo* transcription analyses indicate that the N-terminal acidic activation domain as well as the oligomerization domain is necessary for successful transactivation by wild-type and mutant p53. A high affinity binding site for wild-type p53 within the promoter (-265 to -239) is located just downstream from the major transcriptional start site. Binding to this site wild-type p53 also bends DNA. Using cells devoid of endogenous p53 and *in vivo* transcriptional analysis we show that this binding site is necessary for transcriptional activation by wild-type but not by mutants indicating a difference in their mechanism of action.

The sequence from -105 to -20, previously defined as the basal enhancer/promoter, is sufficient for mutant p53 transcriptional activation. This element contains overlapping binding sites for Sp1 and the Thyroid hormone receptor. *In vivo* binding assays indicate an interaction of Sp1 and p53-281G. Since Sp1-mediated transactivation involves TAF<sub>II</sub>250, we investigated the role of TAF<sub>II</sub>250 in mutant p53-mediated transactivation of the EGFR promoter. *In vivo* transcriptional analyses using BHK-C21-derived ts13 cells with temperature sensitive TAF<sub>II</sub>250 show no transactivation of the EGFR promoter by p53-281G at the nonpermissive (39°C) temperature although significant transactivation can be seen at permissive temperature (30°C). Transactivation at 39°C can be rescued by exogenous TAF<sub>II</sub>250. Transactivation of a synthetic promoter construct containing an ATF-binding site and a TATA box also needed active TAF<sub>II</sub>250. However, wild-type p53 transactivated another synthetic promoter with four p53-binding sites and a TATA element at 39°C indicating that TAF<sub>II</sub>250 is not absolutely essential for transactivation by wild-type p53. Our data thus suggest wild-type and mutant p53 differ in the mechanism of transactivation; mutant p53 may act as a coactivator, and perhaps transactivates the EGFR promoter by interacting with Sp1 requiring TAF<sub>II</sub>250 for its function.